LaunchBio’s NextGen VC Forum is the premiere event for mid-level venture capital associates to expand their skills and expertise while growing their network. Attendees benefit from curated education sessions from industry leaders to supplement existing expertise.
Networking is essential in sourcing deals and one of the primary roles for associates—we’ve built it into the program for participants to be able to walk away with new life science and biotech contacts. The half-day forum includes a networking breakfast, three one-hour sessions and lunch. Attendance at NextGen VC Forum is by invitation only; if interested, please contact your firm’s senior partners.
Agenda
9:00 am Arrival/Check-in/Light Breakfast and Networking
9:45 am Welcome and Introduction – Dan Koeppen & Mike Hostetler
10:00 am Session 1: Executive Compensation – Jody Thelander & Scott McCall
11:00 am Session 2: Navigating Antitrust Regulations – Brendan Coffman & Michelle Yost Hale
12:00 am Lunch/Networking
1:00 pm Session 3: Company Creation – Phil McGill & Deborah Smith
2:00 pm Event Close
The session will review real-time compensation data and trends for venture capital firms across all asset classes and locations. Jody Thelander, Founder & CEO, of the namesake firm, will share exclusive insights and analysis on the various compensation levers, how to utilize them, what filters make a difference in customizing compensation data and what you need to know as you move up the ranks. This session will be interactive.
Speakers: Jody Thelander and Michelle Wallin
Recent challenges and scrutiny of biotech M&A based on novel theories of harm portend that antitrust agencies are aiming to make good on their promise to scrutinize the life science space more closely. In this session, antitrust partners Michelle Hale & Brendan Coffman will discuss the potential impact of these developments on biotech firms and implications for VC investors. Specifically, this session will consider:
• The FTC and DOJ’s approach to merger review, including how the agencies have traditionally defined markets and assessed competitive impact in transactions in the life science space.
• Recent developments in merger enforcement, including the FTC’s recent action to block a transaction involving a venture-backed biotech start-up with no FDA approved products.
• How changes to merger review and enforcement could impact VC investment in the biotech industry.
Speakers: Brendan Coffman and Michelle Yost Hale
As biotech investors, success of your investments hinges not only on groundbreaking science but also on thoughtful company creation. We will delve into the essential steps of how venture capital firms approach company creation, including identifying promising technologies, safeguarding core assets, assembling a talented team, structuring initial funding and enabling future syndication. In addition, we will examine the critical role of intellectual property in evaluating new company opportunities and developing effective strategies for maximizing company value. Through this insightful discussion, we aim to equip you with the knowledge and tools necessary to navigate the complex terrain of company creation and develop the associated core competencies.
Speakers: Phil McGill and Deborah Smith
